Effect of Shilajit Rasayana compound in Diabetic Nerve Damage

RANDOMIZED PLACEBO CONTROLLED DOUBLE BLIND CLINICAL STUDY OF SHILAJIT RASAYANA COMPOUND IN THE MANAGEMENT OF DIABETIC POLYNEUROPATHY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/06/002712

Enrollment

Registered

2012-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetic Distal Symmetric Poly Neuropathy

Interventions

Intervention1: Shilajit Rasayana Compound: 2 capsules 500mg each,twice a day with warm water for duration of 8 weeks Followed by follow up of 4 weeks in both groups with Placebo capsules of Barley f

Eligibility

Inclusion criteria

Inclusion criteria: Metabolically stable Type 2 diabetic patients with symptomatic diabetic sensorimotorpolyneuropathy (DSPN) Patients of either sex between the age group 18â??80 years

Exclusion criteria

Exclusion criteria: 1. Patients with other metabolic and endocrinal disorders. 2. Patients with non-diabetic neuropathies 3. Patients suffering from infectious diseases. 4. Patients with non-healing ulcer/ulcers. 5. Patients with Disabling Diabetic Polyneuropathy

Design outcomes

Primary

Measure	Time frame
Agnibala, Rogabala, and Chetasbala,Quality Of Life(WHO QoL) â?? BREF20, Biothesiometer for quantitative vibration assessment, Michigan Neuropathy Screening Instrument score (MNSI)and Modified Toronto Clinical Neuropathy ScoreTimepoint: 12 weeks (90)	—

Secondary

Measure	Time frame
HBA1cTimepoint: 90days	—

Countries

India

Contacts

Public ContactProf M S Baghel

Institute of Post Gradate Teaching and Research Institute

baghelayu@rediffmail.com09427207964

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026